Knockdown of estrogen receptor β increases proliferation and affects the transcriptome of endometrial adenocarcinoma cells.
Adenocarcinoma
/ genetics
Apoptosis
/ genetics
Cell Differentiation
/ genetics
Cell Line, Tumor
Cell Proliferation
/ genetics
Endometrial Neoplasms
/ genetics
Estrogen Receptor beta
/ genetics
Female
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Gene Knockdown Techniques
Humans
RNA, Small Interfering
/ metabolism
Transcriptome
Transfection
Endometrial cancer
Estrogen receptor β
HEC-1A
RL95/2
Transcriptome analysis
siRNA
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
29 Jul 2019
29 Jul 2019
Historique:
received:
22
11
2018
accepted:
12
07
2019
entrez:
31
7
2019
pubmed:
31
7
2019
medline:
1
1
2020
Statut:
epublish
Résumé
Estrogen receptor β (ERβ) has been repeatedly suggested to play important roles in hormone-dependent cancer like in tumors of the breast, ovary or prostate. In this study, we intended to further elucidate its role in endometrial cancer. For this purpose, we knocked down ERβ expression in two endometrial cancer cell lines, the ERα-negative/ERβ-positive line HEC-1A and the ERα/β-positive cell line RL95/2, by means of siRNA transfection. Cell proliferation after transfection was assessed using the fluorescent CTB Assay (Promega). In order to elucidate possible molecular mechanisms which might underlie the effect on proliferation, we performed transcriptome analyses by means of human Affymetrix Human Gene Chip 2.0. Additionally, we treated the employed cell lines with different ERβ modulators to examine their effect on proliferation. siRNA-mediated knockdown of ERβ significantly increased proliferation of both endometrial cancer cell lines. In HEC-1A cells, proliferation was significantly increased 4, 5 and 6 days after transfection, with a maximum of about 1.7-fold (p < 0.05) on day 6. Endometrial RL95/2 cells with an ERβ knockdown exhibited a clearly enhanced proliferation on day 3 and days 4 to 8, when even 2.4-fold higher numbers of viable cells were detected (p < 0.01). Transcriptome analysis revealed that this was accompanied by increased expression of several genes being known to be upregulated in cancer, including proliferation-associated genes and oncogenes, and by repression of genes associated with differentiation, apoptosis or growth inhibition. Corroborating the observed knockdown effects, treatment with the ERβ antagonists PHTTP and (R, R) THC was also able to induce proliferation of both cell lines. Our data clearly support the putative role of ERβ as tumor suppressor in endometrium as previously suggested in studies on other tissues and encourage further studies to find out to what extent this molecule might be a potential therapy target in this cancer entity.
Sections du résumé
BACKGROUND
BACKGROUND
Estrogen receptor β (ERβ) has been repeatedly suggested to play important roles in hormone-dependent cancer like in tumors of the breast, ovary or prostate. In this study, we intended to further elucidate its role in endometrial cancer.
METHODS
METHODS
For this purpose, we knocked down ERβ expression in two endometrial cancer cell lines, the ERα-negative/ERβ-positive line HEC-1A and the ERα/β-positive cell line RL95/2, by means of siRNA transfection. Cell proliferation after transfection was assessed using the fluorescent CTB Assay (Promega). In order to elucidate possible molecular mechanisms which might underlie the effect on proliferation, we performed transcriptome analyses by means of human Affymetrix Human Gene Chip 2.0. Additionally, we treated the employed cell lines with different ERβ modulators to examine their effect on proliferation.
RESULTS
RESULTS
siRNA-mediated knockdown of ERβ significantly increased proliferation of both endometrial cancer cell lines. In HEC-1A cells, proliferation was significantly increased 4, 5 and 6 days after transfection, with a maximum of about 1.7-fold (p < 0.05) on day 6. Endometrial RL95/2 cells with an ERβ knockdown exhibited a clearly enhanced proliferation on day 3 and days 4 to 8, when even 2.4-fold higher numbers of viable cells were detected (p < 0.01). Transcriptome analysis revealed that this was accompanied by increased expression of several genes being known to be upregulated in cancer, including proliferation-associated genes and oncogenes, and by repression of genes associated with differentiation, apoptosis or growth inhibition. Corroborating the observed knockdown effects, treatment with the ERβ antagonists PHTTP and (R, R) THC was also able to induce proliferation of both cell lines.
CONCLUSIONS
CONCLUSIONS
Our data clearly support the putative role of ERβ as tumor suppressor in endometrium as previously suggested in studies on other tissues and encourage further studies to find out to what extent this molecule might be a potential therapy target in this cancer entity.
Identifiants
pubmed: 31357971
doi: 10.1186/s12885-019-5928-2
pii: 10.1186/s12885-019-5928-2
pmc: PMC6664594
doi:
Substances chimiques
Estrogen Receptor beta
0
RNA, Small Interfering
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
745Références
Endocrinology. 2000 Oct;141(10):3534-45
pubmed: 11014206
J Steroid Biochem Mol Biol. 2001 Apr;77(1):19-27
pubmed: 11358671
Oncogene. 2001 Oct 18;20(47):6965-9
pubmed: 11687977
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Cancer Res. 2002 Nov 1;62(21):6211-7
pubmed: 12414649
J Br Menopause Soc. 2003 Mar;9(1):27-31
pubmed: 12804310
Ginekol Pol. 2003 Sep;74(9):897-902
pubmed: 14674142
FEBS Lett. 2004 May 21;566(1-3):169-72
pubmed: 15147889
J Med Chem. 2004 Nov 18;47(24):5872-93
pubmed: 15537344
Mol Cell Biol. 2005 Jun;25(11):4638-49
pubmed: 15899866
Endocr Relat Cancer. 2005 Dec;12(4):903-16
pubmed: 16322330
Cancer Lett. 2006 Jan 18;231(2):151-7
pubmed: 16399219
Br J Cancer. 2006 Apr 10;94(7):1041-4
pubmed: 16598186
Mol Cell Endocrinol. 2007 Jan 29;264(1-2):50-60
pubmed: 17095148
J Endocrinol. 2007 Jun;193(3):421-33
pubmed: 17535880
Breast Cancer Res Treat. 2008 Aug;110(3):507-20
pubmed: 17876701
Mol Cancer Ther. 2007 Oct;6(10):2626-33
pubmed: 17913855
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
pubmed: 18287387
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
Mol Cell Endocrinol. 2009 Mar 25;301(1-2):74-82
pubmed: 18930784
Appl Immunohistochem Mol Morphol. 2008 Dec;16(6):535-42
pubmed: 18931615
Breast Cancer Res Treat. 2010 Apr;120(3):557-65
pubmed: 19434490
Oncogene. 2009 Oct 29;28(43):3847-56
pubmed: 19684615
Breast Cancer Res Treat. 2011 Oct;129(3):777-84
pubmed: 21120602
PLoS One. 2010 Nov 29;5(11):e14110
pubmed: 21124760
Anticancer Res. 2011 Feb;31(2):711-8
pubmed: 21378361
Climacteric. 2011 Aug;14(4):418-25
pubmed: 21426234
Oncol Rep. 2011 Jul;26(1):145-51
pubmed: 21491086
Leukemia. 2012 Mar;26(3):550-4
pubmed: 21904383
Int J Mol Med. 2012 Jun;29(6):1127-36
pubmed: 22378275
Oncol Rep. 2012 Jun;27(6):2045-9
pubmed: 22427180
PLoS One. 2012;7(9):e44787
pubmed: 22970307
Adv Med Sci. 2013;58(1):96-103
pubmed: 23625281
Chirality. 2013 Oct;25(10):628-42
pubmed: 23925889
Oncol Lett. 2013 Sep;6(3):756-762
pubmed: 24137406
PLoS One. 2014 Apr 30;9(4):e95136
pubmed: 24787708
J Endocrinol. 2014 May 12;221(2):325-36
pubmed: 24819599
Cancer Sci. 2015 Apr;106(4):337-43
pubmed: 25611678
Pharmacol Ther. 2015 Jul;151:16-31
pubmed: 25709099
PLoS One. 2015 Jun 10;10(6):e0129190
pubmed: 26061048
Mol Carcinog. 2016 Nov;55(11):1843-1857
pubmed: 26599461
Vojnosanit Pregl. 2015 Oct;72(10):906-13
pubmed: 26665557
Sci Rep. 2016 Mar 14;6:23100
pubmed: 26972445
Expert Rev Anticancer Ther. 2016 Aug;16(8):827-38
pubmed: 27186719
Nat Rev Urol. 2017 Jan;14(1):38-48
pubmed: 27872477
BMC Cancer. 2016 Dec 21;16(1):951
pubmed: 28003019
BMC Cancer. 2017 May 8;17(1):319
pubmed: 28482871
J Obstet Gynaecol. 2018 Jan;38(1):96-102
pubmed: 28764605
Oncotarget. 2017 Sep 18;8(46):81686-81696
pubmed: 29113424
PLoS One. 2017 Nov 30;12(11):e0188641
pubmed: 29190668
Exp Oncol. 2017 Jul;39(2):145-150
pubmed: 29483489
J Cancer Res Clin Oncol. 2018 Oct;144(10):2067-2076
pubmed: 30083818
Endocr Relat Cancer. 2018 Aug 9;:null
pubmed: 30093601
Cancer Cell. 2018 Aug 13;34(2):346-348
pubmed: 30107180
Nat Protoc. 2019 Mar;14(3):703-721
pubmed: 30804569
N Engl J Med. 1996 Aug 29;335(9):640-9
pubmed: 8692240
Gynecol Oncol. 1996 Oct;63(1):28-33
pubmed: 8898164
Placenta. 1997 Sep;18(7):491-501
pubmed: 9290143